The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Scientists at Georgia State University have used CRISPR gene editing to restore an ancient enzyme humans lost millions of years ago potentially reversing the buildup of uric acid that causes gout.

A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

NEW ORLEANS -- Innovations in lipid lowering get a major chance to shine, and potentially move the needle in cardiometabolic ...

Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital cancer research, offering new insights into potential therapies for the ...

According to the Food and Agriculture Organization (FAO), global food production must increase by 70% by 2050 to sustain the ...